Company attributes
Other attributes
ITM Isotopen Technologien München AG is a biotechnology and radiopharmaceutical group of companies that is dedicated to developing, producing and supplying targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in the treatment of cancer.
ITM and its subsidiaries established GMP manufacturing and a global supply network of a novel, medical radioisotopes and generator platform for a new generation of targeted cancer diagnostics and therapies.
ITM is developing a proprietary portfolio and growing a pipeline of targeted treatments in several stages of clinical development, which address a wide range of cancers such as glioblastoma, neuroendocrine tumors, osteosarcoma and bone metastases, as well as folate receptor α positive tumors like lung, ovarian or breast cancer.
The main objective of ITM Isotopen Technologien München is to improve treatment outcomes and quality of life for cancer patients, reduce side effects and improve health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.
